Literature DB >> 18337712

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes.

F Persson1, P Rossing, K J Schjoedt, T Juhl, L Tarnow, C D A Stehouwer, C Schalkwijk, F Boomsma, E Frandsen, H-H Parving.   

Abstract

Inhibition of renin with an active site inhibitor, aliskiren, lowers blood pressure (BP) in diabetic patients. Here, we studied the time course of the antihypertensive and antiproteinuric effect of renin inhibition in 15 patients with type 2 diabetes and elevated urinary albumin/creatinine ratios (UACRs) to check whether aliskiren can decrease proteinuria. After a 4-week washout of previous medications, patients received aliskiren and furosemide daily for 28 days followed by a 4-week withdrawal period. Twenty-four-hour BPs were measured at baseline throughout treatment and withdrawal periods. The UACR was significantly reduced after 2-4 days of treatment with another significant reduction after 28 days. Systolic blood pressure (SBP) was significantly lower after 7 days with no further reduction after 28 days. The BP returned toward baseline 3 days after withdrawal, whereas the UACR was still significantly reduced compared with baseline 12 days after withdrawal. Our study shows that aliskiren reduced 24 h SBP, and this was associated with a reduction in albuminuria in type 2 diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18337712     DOI: 10.1038/ki.2008.68

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  41 in total

1.  Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats.

Authors:  Luis C Matavelli; Jiqian Huang; Helmy M Siragy
Journal:  J Cardiovasc Pharmacol       Date:  2012-03       Impact factor: 3.105

Review 2.  Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities.

Authors:  Massimo Volpe; Roberto Pontremoli; Claudio Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-09-01

Review 3.  Direct renin inhibitors: ONTARGET for success?

Authors:  Yasmin Pasha; Paul Gusbeth-Tatomir; Adrian Covic; David Goldsmith
Journal:  Int Urol Nephrol       Date:  2009-03-19       Impact factor: 2.370

Review 4.  Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.

Authors:  Carlos M Ferrario
Journal:  Life Sci       Date:  2009-12-01       Impact factor: 5.037

Review 5.  What is the role of renin inhibition in the treatment of diabetic kidney disease?

Authors:  Radko Komers
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

Review 6.  Application of direct renin inhibition to chronic kidney disease.

Authors:  Christian W Mende
Journal:  Cardiovasc Drugs Ther       Date:  2010-04       Impact factor: 3.727

Review 7.  Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.

Authors:  Francesca Cagnoni; Christian Achiri Ngu Njwe; Augusto Zaninelli; Alessandra Rossi Ricci; Diletta Daffra; Antonio D'Ospina; Paola Preti; Maurizio Destro
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

Review 8.  New class of agents for treatment of hypertension: focus on direct renin inhibition.

Authors:  Roberto Fogari; Annalisa Zoppi
Journal:  Vasc Health Risk Manag       Date:  2010-10-05

9.  Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.

Authors:  Frederik Persson; Peter Rossing; Henrik Reinhard; Tina Juhl; Coen D A Stehouwer; Casper Schalkwijk; A H Jan Danser; Frans Boomsma; Erik Frandsen; Hans-Henrik Parving
Journal:  Diabetes Care       Date:  2009-07-08       Impact factor: 19.112

Review 10.  Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.

Authors:  Eduardo Pimenta; Suzanne Oparil
Journal:  Vasc Health Risk Manag       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.